Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05759338
Other study ID # IRB00094234
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 10, 2023
Est. completion date November 2024

Study information

Verified date January 2024
Source Wake Forest University Health Sciences
Contact Ivie M Obeime, D.O.
Phone 336-716-3926
Email iobeime@wakehealth.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if the Revian Red All LED cap shows potential to be an effective treatment for Central centrifugal cicatricial alopecia (CCCA) by recruiting hair follicles back to anagen growth or by improving inflammation. The primary outcome is to determine if hair loss regression is halted. Secondary outcomes include hair regrowth and alleviation of signs and symptoms of the disease. Participants will be asked to use the Revian Red All LED cap once daily for a 10-minute treatment regimen which is the current androgenetic alopecia recommendation.


Description:

Subjects who are willing to participate in a novel treatment for Revian Red All LED cap will be enrolled in this study. The cap uses two wavelengths of light, 620 nm and 660 nm. A study cap will be provided for each subject. Subjects will use the cap once daily, 10-minute treatment regimen which is the current androgenetic alopecia recommendation. The subjects will use the cap for a total of 6 months. To use the cap, subjects will connect the Revian Red All LED cap to a Smart App on a mobile phone device using Bluetooth. Subjects can use the Smart App to set daily reminders to use the cap, track and log usage, and use the 10 minute timer. No additional information will be stored on the Smart App. Only subjects will have access to the Smart App located on their personal mobile phone device. Standardized photos and trichoscopic photos before starting treatment and every 2 months for x 6 total months will be taken to assess hairline stabilization and potential for regrowth. A baseline photo and completion photo will also be taken with a visio device. This will help determine pigmentation of the present hairs throughout the study. Prior to study enrollment, all participants will receive a detailed explanation of the purpose of the study and will undergo written informed consent. Clinical history of hair loss and history of prior treatment will be obtained by administering a standardized questionnaire to all subjects. Subjects will also fill out a questionnaire regarding symptoms of their hair loss at each visit. There will be 4 visits total (1 Pre-treatment visit and 3 Follow up visits).


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date November 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Women who are between the age of eighteen years and sixty-five years - Biopsy-proven diagnosis of CCCA Stage II-IV. - Must be on stable treatment without changes (on doxycycline, topical steroids, minoxidil and/or post 8 rounds of intralesional steroids) for at least 3 months Exclusion Criteria: - Subjects with other forms of hair loss that is not CCCA - Prior treatment with light source for alopecia - Males are excluded from this study since the prevalence of CCCA in males is so significantly low that it is difficult to find cases in a clinical setting

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Revian Red All LED cap
The cap is a dual-band LED light therapy wireless "smart" cap. It has been shown to be effective in androgenetic alopecia (used once daily, 10-minute treatment regimen) for both men and women.

Locations

Country Name City State
United States Wake Forest University Health Sciences, Dermatology Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Shape of the hairline documented with photographs Photographs of the stabilization and regrowth of the hairline documented by standardized camera and dermatoscopic photographs of the scalp Baseline
Primary Shape of the hairline documented with photographs Photographs of the stabilization and regrowth of the hairline documented by standardized camera and dermatoscopic photographs of the scalp month 2
Primary Shape of the hairline documented with photographs Photographs of the stabilization and regrowth of the hairline documented by standardized camera and dermatoscopic photographs of the scalp month 4
Primary Shape of the hairline documented with photographs Photographs of the stabilization and regrowth of the hairline documented by standardized camera and dermatoscopic photographs of the scalp month 6
Secondary Change in hairline assessment scores by participant Subjects will complete the standardized questionnaire regarding symptoms of their hair loss: Perception Dermatology Life Quality Index (DLQI) survey - The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired. The DLQI can also be expressed as a percentage of the maximum possible score of 30. Baseline and month 6
Secondary Change in Perifollicular scale Assessments of hairline change by study physician Scalp and hair exam and assessment with completion of grader survey to measure: Perifollicular scale
Mild - affecting <10% of scalp. Moderate - affecting 10-30% of scalp. Severe - affecting >30% of scalp. For all signs other than Vellus/Intermediate/Terminal hair shafts: Percentage of types of hair shafts
Baseline, month 2, month 4, month 6
Secondary Change in Hyperpigmentation Assessments of hairline change by study physician Scalp and hair exam and assessment with completion of grader survey to measure: Hyperpigmentation
Mild - affecting <10% of scalp. Moderate - affecting 10-30% of scalp. Severe - affecting >30% of scalp. For all signs other than Vellus/Intermediate/Terminal hair shafts: Percentage of types of hair shafts
Baseline, month 2, month 4, month 6
Secondary Change in Breakage Assessments of hairline change by study physician Scalp and hair exam and assessment with completion of grader survey to measure: Breakage
Mild - affecting <10% of scalp. Moderate - affecting 10-30% of scalp. Severe - affecting >30% of scalp. For all signs other than Vellus/Intermediate/Terminal hair shafts: Percentage of types of hair shafts
Baseline, month 2, month 4, month 6
Secondary Change in Interfollicular scale Assessments of hairline change by study physician Scalp and hair exam and assessment with completion of grader survey to measure: Interfollicular scale
Mild - affecting <10% of scalp. Moderate - affecting 10-30% of scalp. Severe - affecting >30% of scalp. For all signs other than Vellus/Intermediate/Terminal hair shafts: Percentage of types of hair shafts
Baseline, month 2, month 4, month 6
Secondary Change in Erythema Assessments of hairline change by study physician Scalp and hair exam and assessment with completion of grader survey to measure: Erythema
Mild - affecting <10% of scalp. Moderate - affecting 10-30% of scalp. Severe - affecting >30% of scalp. For all signs other than Vellus/Intermediate/Terminal hair shafts: Percentage of types of hair shafts
Baseline, month 2, month 4, month 6
Secondary Change in Loss of follicular openings Assessments of hairline change by study physician Scalp and hair exam and assessment with completion of grader survey to measure: Loss of follicular openings
Mild - affecting <10% of scalp. Moderate - affecting 10-30% of scalp. Severe - affecting >30% of scalp. For all signs other than Vellus/Intermediate/Terminal hair shafts: Percentage of types of hair shafts
Baseline, month 2, month 4, month 6
Secondary Change in Vellus/Intermediate/Terminal hair shafts Assessments of hairline change by study physician Scalp and hair exam and assessment with completion of grader survey to measure: Vellus/Intermediate/Terminal hair shafts
Mild - affecting <10% of scalp. Moderate - affecting 10-30% of scalp. Severe - affecting >30% of scalp. For all signs other than Vellus/Intermediate/Terminal hair shafts: Percentage of types of hair shafts
Baseline, month 2, month 4, month 6
See also
  Status Clinical Trial Phase
Completed NCT03521687 - Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA) Phase 4
Not yet recruiting NCT05416333 - Azelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) Early Phase 1
Recruiting NCT04764331 - A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia N/A
Completed NCT03346668 - Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia Early Phase 1
Withdrawn NCT05416320 - Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) Early Phase 1
Completed NCT03044782 - Barriers to Care and QOL for CCCA Patients N/A
Completed NCT04342091 - Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling N/A